Advertisement
Advertisement
U.S. Markets close in 1 hr 29 mins
Advertisement
Advertisement
Advertisement
Advertisement

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.67-0.71 (-6.24%)
As of 04:00PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.38
Open11.44
Bid9.80 x 900
Ask10.74 x 900
Day's Range10.48 - 11.44
52 Week Range10.08 - 29.80
Volume96,874
Avg. Volume93,888
Market Cap278.289M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-4.64
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.83
  • GlobeNewswire

    Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism

    NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced a symposium and poster presentations at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), November 21-23, 2021, Sydney, Australia. “We are pleased to present this important data at the ICIEM conference, demon

  • Simply Wall St.

    Great news for Applied Therapeutics, Inc. (NASDAQ:APLT): Insiders acquired stock in large numbers last year

    Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

  • GlobeNewswire

    Applied Therapeutics Reports Third Quarter 2021 Financial Results

    Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant reduction in plasma galactitol NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported fin

Advertisement
Advertisement